A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).
A Phase 2, Open-label, Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel in Patients With Active, Refractory Systemic Lupus Erythematosus (SLE) or Active, Refractory Lupus Nephritis (LN).
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
novartis.email@novartis.com1-888-669-6682
novartis.email@novartis.com+41613241111
Birmingham, Alabama 35294, United States
llaupus@uabmc.edu205-996-7438
Bunkyo Ku, Tokyo 1138431, Japan
Bunkyo-ku, Tokyo 1138519, Japan
Santiago Compostela, A Coruna 15706, Spain
alejandrabeltran@llu.edu909-651-1002
Zilan.Zheng@ucsf.edu415-353-1301
zilan.zheng@ucsf.edu
canary.jumawan@sutterhealth.org
errbrown@luriechildrens.org
kaitlin.king@nm.org
darby-donovan@uiowa.edu319-356-2197
dross3@email.uky.edu
angela.chavez@tuftsmedicine.org617-636-6227
Bharath.Miriyam@bmc.org617-638-9136
sewellm@wustl.edu314-454-8293
Eileen.phifer@duke.edu
melz@ohsu.edu503-494-9021
mtaylor5@houstonmethodist.org
CCMusni@mdanderson.org
msalmazor@mdanderson.org713-563-0020
tina.hockett@imail.org801-408-4712
tara.sou@imail.org801-408-1100